Over-prescription of short-acting β2-agonists for asthma in South Africa: Results from the SABINA III study
Article Sidebar
Main Article Content
Abstract
Background. Asthma medication prescription trends, including those of short-acting β2-agonists (SABAs), are not well documented for South Africa (SA).
Objectives. To describe demographics, disease characteristics and asthma prescription patterns in the SA cohort of the SABA use IN Asthma (SABINA) III study.
Methods. An observational, cross-sectional study conducted at 12 sites across SA. Patients with asthma (aged ≥12 years) were classified by investigator-defined asthma severity, guided by the Global Initiative for Asthma (GINA) 2017 recommendations, and practice type (primary/ specialist care). Data were collected using electronic case report forms.
Results. Overall, 501 patients were analysed − mean (standard deviation) age, 48.4 (16.6) years; 68.3% female − of whom 70.6% and 29.4% were enrolled by primary care physicians and specialists, respectively. Most patients were classified with moderate-to-severe asthma (55.7%; GINA treatment steps 3 - 5), were overweight or obese (70.7%) and reported full healthcare reimbursement (55.5%). Asthma was partly controlled/uncontrolled in 60.3% of patients, with 46.1% experiencing ≥1 severe exacerbations in the 12 months before the study visit. Overall, 74.9% of patients were prescribed ≥3 SABA canisters in the previous 12 months (over-prescription); 56.5% were prescribed ≥10 SABA canisters. Additionally, 27.1% of patients reported purchasing SABA over-the-counter (OTC); among patients with both SABA purchase and prescriptions, 75.4% and 51.5% already received prescriptions for ≥3 and ≥10 SABA canisters, respectively, in the preceding 12 months.
Conclusion. SABA over-prescription and OTC purchase were common in SA, demonstrating an urgent need to align clinical practices with the latest evidence-based recommendations and regulate SABA OTC purchase to improve asthma outcomes.
Downloads
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
Schellack N, Truter A, Ntuli PN. Approach to asthma in adults. S Afr Fam Pract 2015;57(4):31-36. https://doi.org/10.1080/20786204.2004.10873087
The Global Asthma Report 2018. http://globalasthmareport.org/Global%20 Asthma%20Report%202018.pdf (accessed 26 October 2022).
Masekela R, Gray CL, Green RJ, et al. The increasing burden of asthma in South African children: A call to action. S Afr Med J 2018;108(7):537-539. https://doi. org/10.7196/SAMJ.2018.v108i7.13162
Zar HJ, Lalloo UG. Acute asthma treatment guidelines: Reducing morbidity and mortality in South Africa. S Afr Med J 2013;103(3):159-160. https://doi.org/10.7196/ samj.6791
Mash B, Rhode H, Pather M, et al. Quality of asthma care: Western Cape Province, South Africa. S Afr Med J 2009;99(12):892-896.
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2022. www.ginasthma.org (accessed 26 October 2022).
Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short- acting β(2)-agonists in asthma is associated with increased risk of exacerbation and mortality: A nationwide cohort study of the global SABINA programme. Eur Respir J 2020;55(4):1901872. https://doi.org/10.1183/13993003.01872-2019
Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β(2)-agonist inhaler use: An observational UK study as part of the SABINA Global Program. Adv Ther 2020;37(10):4190-4208. https://doi.org/10.1007/ s12325-020-01444-5
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2019. www.ginasthma.org (accessed 26 October 2022).
Cabrera CS, Nan C, Lindarck N, Beekman M, Arnetorp S, van der Valk RJP. SABINA: Global programme to evaluate prescriptions and clinical outcomes related to short- acting beta2-agonist use in asthma. Eur Respir J 2020;55(2): 1901858. https://doi. org/10.1183/13993003.01858-2019
Bateman ED, Price DB, Wang H, et al. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: The multi-country, cross- sectional SABINA III study. Eur Respir J 2022; 59(5):2101402. https://doi. org/10.1183/13993003.01402-2021
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2017. www.ginasthma.org (accessed 26 October 2022).
Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/ European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180(1):59-99. https://doi.org/10.1164/rccm.200801-060ST
Baard CB, Franckling-Smith Z, Munro J, Workman L, Zar HJ. Asthma in South African adolescents: A time trend and risk factor analysis over two decades. ERJ Open Res 2021;7(2):00576-2020. https://doi.org/10.1183/23120541.00576-2020
Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011;377(9765):557-567. https://doi.org/10.1016/S0140-6736(10)62037-5
Cois A, Day C. Obesity trends and risk factors in the South African adult population. BMC Obes 2015;2:42. https://doi.org/10.1186/s40608-015-0072-2
Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: The REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24:14009. https://doi.org/10.1038/ npjpcrm.2014.9
Fletcher MJ, Tsiligianni I, Kocks JWH, et al. Improving primary care management of asthma: Do we know what really works? NPJ Prim Care Respir Med 2020;30(1):29. https:// doi.org/10.1038/s41533-020-0184-0
Levy ML. The national review of asthma deaths: What did we learn and what needs to change? Breathe (Sheff ) 2015;11(1):14-24. https://doi.org/10.1183/20734735.008914
Levy ML. Guideline-defined asthma control: A challenge for primary care. Eur Respir J
;31(2):229-231. https://doi.org/10.1183/09031936.00157507
Irving G, Neves AL, Dambha-Miller H, et al. International variations in primary
care physician consultation time: A systematic review of 67 countries. BMJ Open
;7(10):e017902. https://doi.org/10.1136/bmjopen-2017-017902
Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: Prevalence, detection and consequences in general practice. Eur Respir J 2008;31(2):320-325. https://
doi.org/10.1183/09031936.00039707
Baddar S, Jayakrishnan B, Al-Rawas O, George J, Al-Zeedy K. Is clinical judgment of asthma control adequate? A prospective survey in a tertiary hospital pulmonary clinic. Sultan Qaboos Univ Med J 2013;13(1):63-68. https://doi.org/10.12816/0003197
BouletLP,PhillipsR,O’ByrneP,BeckerA.Evaluationofasthmacontrolbyphysiciansand patients: Comparison with current guidelines. Can Respir J 2002;9(6):417-423. https://doi. org/10.1155/2002/731804
Ponte EV, Petroni J, Ramos DC, Pimentel L, Freitas DN, Cruz AA. [Perception of asthma control in asthma patients]. J Bras Pneumol 2007;33(6):635-640. https://doi.org/10.1590/ s1806-37132007000600005
Ding B, Small M. Disease burden of mild asthma: Findings from a cross-sectional real- world survey. Adv Ther 2017;34(5):1109-1127. https://doi.org/10.1007/s12325-017- 0520-0
Muneswarao J, Hassali MA, Ibrahim B, Saini B, Ali IAH, Verma AK. It is time to change the way we manage mild asthma: An update in GINA 2019. Respir Res 2019;20(1):183. https://doi.org/10.1186/s12931-019-1159-y
Price D, David-Wang A, Cho SH, et al. Time for a new language for asthma control: Results from REALISE Asia. J Asthma Allergy 2015;8:93-103. https://doi.org/10.2147/ JAA.S82633
Myers B, Siegfried N, Parry CD. Over-the-counter and prescription medicine misuse in Cape Town--findings from specialist treatment centres. S Afr Med J 2003;93(5):367-370. 30. Gibson P, Henry D, Francis L, et al. Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma. BMJ (Clinical Research Ed)
;306(6891):1514-1518. https://doi.org/10.1136/bmj.306.6891.1514
Reddel HK, Ampon RD, Sawyer SM, Peters MJ. Risks associated with managing asthma without a preventer: Urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open 2017;7(9):e016688. https://doi.
org/10.1136/bmjopen-2017-016688
Ferris TG, Blumenthal D, Woodruff PG, Clark S, Camargo CA. Insurance and quality of care for adults with acute asthma. J Gen Intern Med 2002;17(12):905-913. https://doi. org/10.1046/j.1525-1497.2002.20230.x
Price D, Castro M, Bourdin A, Fucile S, Altman P. Short-course systemic corticosteroids in asthma: Striking the balance between efficacy and safety. Eur Respir Rev 2020;29(155):190151. https://doi.org/10.1183/16000617.0151-2019
Manderson L. Prescribing, care and resistance: Antibiotic use in urban South Africa. Humanit Soc Sci Commun 2020;7(1):77. https://doi.org/10.1057/s41599-020-00564-1
Green R, Davis G, Price D. Perceptions, impact and management of asthma in South Africa: A patient questionnaire study. Prim Care Respir J 2008;17(4):212-216. https://doi. org/10.3132/pcrj.2008.00027
GreenRJ,GreenblattMM,PlitM,JonesS,AdamB.Asthmamanagementandperceptions in rural South Africa. Ann Allergy Asthma Immunol 2001;86(3):343-347. https://doi. org/10.1016/S1081-1206(10)63311-X
Greenblatt M, Galpin JS, Hill C, Feldman C, Green RJ. Comparison of doctor and patient assessments of asthma control. Respir Med 2010;104(3):356-361. https://doi. org/10.1016/j.rmed.2009.10.010
3LallooUG,KallaIS,Abdool-GaffarS,etal.;AsthmaWorkingGroupoftheSouthAfrican Thoracic Society. Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society - 2021 update. Afr J Thorac Crit Care Med 2021;27(4):10.7196. https://doi.org/10.7196/AJTCCM.2021.v27i4.189
VerweyC.TheNationalAsthmaEducationProgrammeandAsthmainAfrica.SAfrMed J 2019;109(7):453-454. https://doi.org/10.7196/SAMJ.2019.v109i7.14090